Bad medicine

Re “Generic solution,” editorial, Feb. 24

The problem facing seniors in the availability of low-cost generics is further illustrated by the formulary of one of the state’s largest Medicare Part D providers. Although the brand-name drug is available under the formulary, the generic is not, thus increasing the cost of the prescription drug to the senior consumer.

By including only the brand-name product, the cost to the Medicare recipient is increased, which may provide a greater profit to the Part D provider.

How many other low-cost generics are denied to Medicare Part D subscribers?

SELWYN BRENT

Huntington Beach